Warner-Lambert Co.

作者｜零星 自身免疫疾病（AID）是指机体免疫系统对自身组织或细胞的攻击所引发的一类疾病，包括类风湿性关节炎、系统性红斑狼疮、炎性肠病等。 随着科学研究的深入发展和治疗方法的创新，自免并购活动在过去几十年中不断增加，推动了行业的快速发展。本文简要梳理！   01   自免并购的早期阶段: 20世纪末期 20世纪末期，各大生物技术和制药公司开始认识到自身免疫疾病治疗市场的潜力，虽然这一时期行业内相关的并购活动相对较少，但仍为后续蓬勃发展的市场以及并购活动的发展奠定了一定基础。 这一时期重要的并购案包括： 53亿美元：罗氏收购Syntex（1994） 罗氏（Roche）以53亿美元收购美国生物技术公司Syntex，帮助罗氏加强了在风湿性关节炎和其他自免疾病治疗领域的产品组合； 图2：《芝加哥论坛报》报道罗氏收购Syntex的新闻 820亿美元：辉瑞收购Warner-Lambert（1999） 辉瑞（Pfizer）以约820亿美元的价格收购了Warner-Lambert。这次并购虽然主要是为了取得著名的降胆固醇药物立普妥（Lipitor），但也极大增强了辉瑞在自身免疫疾病药物开发方面的实力。 图3：《华盛顿邮报》辉瑞收购Warner-Lambert的新闻 赛诺菲-安万特（Sanofi-Aventis）成立（1999） 1999年，赛诺菲（Sanofi）和霍诺（Hoechst Marion Roussel）合并成立了赛诺菲-安万特（Sanofi-Aventis），这次合并使赛诺菲在自身免疫疾病治疗领域拥有更强的研发能力和市场份额。 图4：赛诺菲（Sanofi）和霍诺（Hoechst Marion Roussel）的相关报道 160亿美元：Amgen收购Immunex（2001） 在这一时期，还有一个典型的收购案例，2001年，Amgen以160亿美元收购Immunex，获取了其重磅药物Enbrel（依那西普）。Enbrel是一种抗肿瘤坏死因子（TNF）药物，主要用于治疗类风湿性关节炎和其他自身免疫疾病。这次收购不仅使得Amgen在免疫疾病治疗领域的地位显著提升，也为其带来了可观的财务回报 。 图5：Nature Technology网站对Amgen收购Immunex的报道 图6：Amgen官网新闻 自身免疫领域（自免领域）的并购案反映了生物技术和制药行业的整合趋势这些并购案不仅加速了自身免疫疾病治疗药物的开发和上市，也推动了生物技术和制药行业的整合和创新。通过并购，这些公司能够获取更多的资源、技术和市场，进而提升其竞争力和市场地位。   02   自免并购的汹涌浪潮：2015~2020 进入21世纪第二个十年，自身免疫疾病治疗市场迅速扩展，生物技术的进步和新疗法的开发推动了大量并购交易。 这十年间，若干生物技术和制药公司纷纷加入并购浪潮，自免领域并购案例如雨后春笋般涌现，时常占据医药行业新闻头条，引起国内外众多关注。 210亿美元：AbbVie收购Pharmacyclics（2015） 2015年AbbVie以210亿美元的价格收购了Pharmacyclics，通过本次收购，Abbvie获得了Pharmacyclics的于治疗多种血液系统疾病的药物Imbruvica（依鲁替尼）。虽然Imbruvica主要用于癌症治疗，但其研究成果为自身免疫疾病治疗提供了新的思路，并增强了AbbVie在免疫学领域的研发能力 。 图7：AbbVie官网并购内容 72亿美元：Celgene收购Receptos（2015） Celgene以72亿美元收购Receptos，主要是为了其在研药物Ozanimod，这是一种用于治疗多发性硬化症和溃疡性结肠炎的S1P受体调节剂。Ozanimod的开发成功使Celgene在自身免疫疾病治疗领域的布局更加完善 。 图8：Market Screen对此次并购的相关报道 25亿美元：Sanofi收购Synthorx（2019） 2019年，Sanofi收购Synthorx。Sanofi以25亿美元收购了Synthorx，获取其以工程化IL-2为基础的免疫治疗技术。Synthorx的技术平台旨在增强免疫系统的选择性，开发新型治疗方法来治疗癌症和自身免疫疾病，进一步拓展了Sanofi在免疫治疗领域的产品线 。 图9：Sanofi官网对此次并购的说明   03   自免并购继续升温：近五年情况 再把视野转向2020年至今，我们可以直观地看到，在过去的几年中，自身免疫领域的并购活动继续升温，主要驱动力包括对创新疗法的需求、企业间的战略整合以及资本市场的支持。 3.1亿美元：Novartis收购IFM Therapeutics的自身免疫部门（2020） 2020年，Novartis收购IFM Therapeutics的自身免疫部门。Novartis以3.1亿美元的价格收购了IFM Therapeutics的自身免疫资产。这些资产包括多个用于治疗自身免疫疾病的小分子药物，旨在通过靶向炎症信号通路来调节免疫反应，极大地增强了Novartis在自身免疫治疗领域的研发能力。 图10：Fierce Biotech网站对此次收购的报道 390亿美元：AstraZeneca收购Alexion Pharmaceuticals（2021） 2021年，AstraZeneca收购Alexion Pharmaceuticals。 AstraZeneca以390亿美元的价格收购了Alexion Pharmaceuticals，这是近年来规模最大的并购案之一。Alexion是开发罕见病和自身免疫疾病治疗药物的领导者，其主要产品Soliris和Ultomiris用于治疗一系列罕见的自身免疫疾病。这次收购使AstraZeneca在免疫学和罕见病领域的地位显著提升。 图11：Pharmaceutical Technology网站对此次并购的报道 自2019年受到COVID-19新冠疫情的影响，资金短缺与市场不确定性、监管审批延误、临床试验停滞、供应链中断、战略优先级变化等多方面的影响和挑战，制药和生物技术行业相关自身免疫疾病领域的并购活动相对减少，但是趋势仍不容忽略。   04   自免并购案屡见不鲜的2024年 让我们目光再转回到2024年，截至五月底，自免相关的并购、收购案例屡见不鲜，并购活动呈现活跃态势。这里聚焦几个比较典型的案例： 2.5亿美元：Novartis收购Calypso Biotech（2024.01） 1月，Novartis以2.5亿美元的价格收购了Calypso Biotech，这家公司开发的CALY-002针对IL-15，用于治疗乳糜泻和嗜酸性食管炎。Novartis计划利用该产品针对多种高未满足需求的自身免疫病适应症进行开发。 图12：European Biotechnology网站关于此次并购的报道 Regeneron收购2seventy Bio的肿瘤和自身免疫资产（2024.04） 4月，Regeneron收购了2seventy Bio的肿瘤和自身免疫资产，并成立了新的研发部门Regeneron Cell Medicine。此次收购包括雇佣了2seventy Bio的160名员工，初步将重点放在CAR-T和CAR-NK疗法的开发上。 图13：Regeneron官网对此次收购的相关内容 Eliem Therapeutics收购Tenet Medicines（2024.04） 同月，Eliem Therapeutics收购了Tenet Medicines，其主要资产是抗CD19抗体TNT119，潜在适应症包括系统性红斑狼疮（SLE）和免疫性血小板减少症等。此次收购使Eliem能够扩展其在自身免疫疾病治疗领域的产品线。 图14：Eliem官网对此次收购的相关内容 强生收购Numab、Ashahi Kasei Corporation收购Calliditas（2024.05） 本文开篇就已经提到，今年5月强生并购Numab，同时五月还有几起自免领域相关的并购案，就在强生并购案的当天，日本化工企业旭化成（Ashahi Kasei Corporation）也宣布准备以10.6亿美元收购瑞典生物技术公司Calliditas Therapeutics，本次收购后，旭化成将获得Calliditas的Nefecon（用以治疗IgA肾病）等。 图15：Ashahi Kasei Corporation公司对本次收购的相关内容   写在最后   随着2024年下半年的到来，预计自身免疫领域的并购活动将继续活跃。 各大生物科技和医药公司将继续通过战略性收购和合作，寻求在自身免疫疾病治疗领域的突破和创新。这些并购活动不仅有助于提升公司在市场上的竞争力，还将加速新疗法的开发和商业化进程，为患者带来更多的治疗选择和希望。 参考资料： [1]强生官网；Numab官网；Amgen官网；AbbVie官网；Sanofi官网；Novartis年报；Regeneron官网；Eliem官网 [2] Switzerland’s Roche Holding Ltd. agreed to buy Syntex Corp. for $5.3 billion [3] Pfizer Bids $82 Billion for Warner-Lambert [4] Amgen's big-ticket play for Immunex [5] Novartis ponies up $310M for IFM Therapeutics’ inflammation-focused unit [6] Novartis AG to buy immunology specialist Calypso Biotech BV [7] J&J to Acquire Rights to Investigational Bispecific Antibody 10.12日，深圳；BiG第二届自免研讨会 8:50-8:55 联合主办方致辞 张  战：卫光控股董事长、卫光生物董事长 8:55-9:00 联合主办方致辞 涂   欢：深圳医学科学院副院长、深圳湾实验室副主任 9:00-9:30 Keynote—炎症免疫检查点与AI驱动药物研发 陈有海：美国医学与生物工程院士、欧洲科学院院士、深圳理工大学药学院院长 9:30-10:00 Keynote—临床视角，创新药开发自免，如何选择适应症？ 徐沪济：海军军医大学长征医院大内科主任兼风湿科主任/清华大学医学院教授 10:00-10:25 MNC视角，AZ在肿瘤+自免的布局和开发策略 章   宇： 阿斯利康产品管线和项目管理副总裁 10:25-10:50 茶歇 10:50-11:40 Panel：自免创新药如何立项？MNC&biotech的布局策略，BD合作背后的故事？ 肖昌春：赛诺菲中国研究负责人、赛诺菲研究院负责人 徐亚南：武田制药全球外部创新合作部中国区负责人 邓天敬：炎明生物联合创始人/CEO 靳照宇：明济生物董事长兼CEO 朱向阳：华奥泰生物总经理 周潇薇：松禾资本董事总经理（主持） 11:40-12:30 Panel：从肿瘤转战自免，创新疗法（CAR-T/CAR- NK/双抗/ADC/PROTAC等）如何选择适应症，不同modality各自开发优势及挑战，在哪里？未来有哪些新靶标值得关注？ 范晓虎：湾岛细胞创始人/CEO 花海清：映恩生物研发副总裁 冯   焱：领泰生物创始人/CEO 张   雷：深圳湾实验室特聘研究员 卢宏韬：科望医药联合创始人/CSO、BiG总干事（主持） 12:30 闭幕致辞&研讨会主持 李  圆：BiG秘书长 12:30-14:00 午餐&参观&自由交流 ● 深圳医学科学院（SMART）、卫光生命科学园、湾有引力（光明生物医药创新中心） 报名入口  PS：免费席位有限，均为审核制 观众门票：0元 含12日自免会议&午餐；限biotech/Pharma、临床、院校科学家、投资机构代表 共建Biomedical创新生态圈！ 如何加入BiG会员？

Queen Silvia of Sweden and U.S. Ambassador to Sweden Attended in Support of Mission to Fight Alzheimer's Disease NEW YORK, Sept. 12, 2024 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) held its prestigious Tenth Annual Melvin R. Goodes Prize internationally for the first time in Stockholm, Sweden from September 8-10. This esteemed annual award honors a leading scientist for their exceptional contributions to Alzheimer's research, underscoring the global fight against Alzheimer's disease and related dementias. This year's Goodes Prize recognized Henrik Zetterberg, MD, PhD, a biomarker expert from Sweden, who is a pioneer in the Alzheimer's field and has spent the last 15 years focusing on the development of biomarkers for Alzheimer's and other neurodegenerative diseases. The three-day event featured a series of scientific lectures at the renowned Karolinska Institute spotlighting significant research achievements from previous Goodes Prize winners. In honor of the occasion, Queen Silvia of Sweden attended and gave remarks congratulating the scientists. To commemorate the 10th anniversary of the Goodes Prize, all past laureates were also honored during a special dinner and ceremony on Tuesday, September 10 at the iconic Stockholm City Hall, where U.S. Ambassador to Sweden Erik Ramanathan and ADDF Board Co-Vice Chair and Secretary Randal Sandler presented commemorative medals to the prize recipients. The celebration brought together leaders from academia, industry, and philanthropy to recognize these exceptional researchers and to foster collaboration toward a future free of Alzheimer's. "My brother and I founded the ADDF because we saw the urgent need for effective treatments for Alzheimer's," said Leonard A. Lauder, Co-Founder and Co-Chairman of the ADDF. "It is incredibly meaningful for us to gather the world's top researchers and support their work through the Goodes Prize. Their research, along with the leadership of the ADDF, is changing the course of this disease and getting us closer to making Alzheimer's a thing of the past." "I am so proud to see how the Goodes Prize has not just evolved but has become one of the key assets in the battle against Alzheimer's disease," said Ronald S. Lauder, Co-Founder and Co-Chairman of the ADDF. "Since we began this award ten years ago, each of its recipients has made such important contributions to the science and knowledge of Alzheimer's. Because of them, we are closer than ever to having multiple treatments, better diagnostic tools, and effective prevention methods that we can combine to defeat this disease. I am so proud of these great scientists." Established in honor of Melvin R. Goodes, former CEO of Warner-Lambert Company who channeled his unique knowledge of the drug industry into Alzheimer's advocacy after being diagnosed with the disease, the Melvin R. Goodes Prize for Excellence in Drug Development celebrates groundbreaking innovation and perseverance in the quest for effective treatments for Alzheimer's. The award recognizes individual researchers whose work has greatly advanced our understanding of Alzheimer's mechanisms, biomarkers, or therapeutic strategies, paving the way for potential breakthroughs in treatment and prevention. "The Goodes Prize underscores our commitment to advancing drug development for Alzheimer's disease," said Dr. Howard Fillit, Co-Founder and Chief Science Officer of the ADDF. "Hosting this year's event in Sweden—home of the Nobel Prize—is symbolic of the Goodes Prize's esteem within the Alzheimer's community. This special occasion highlights the ADDF's vital role on the global stage and our dedication to spearheading Alzheimer's research worldwide." Prominent Palm Beach residents and ADDF supporters in attendance included Gary Lauder, Anita Cosgrove, Chip DiPaola, Ann Jackson and Ken Wilson, Angela Kumble, Bonnie Pfeifer Evans, Julie Geier, Nancy Goodes, Peter and Deborah Krulewitch, Laura Landro and Rick Salomon, Sharon Sager, Caroline Fitzgibbons and Tad Smith, Bonnie and Tom Strauss, and other distinguished guests. For more information about the Melvin R. Goodes Prize and this year's award recipient, please visit the event webpage. About the Alzheimer's Drug Discovery Foundation (ADDF) Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer's disease. The ADDF is the only public charity solely focused on funding the development of drugs for Alzheimer's, employing a venture philanthropy model to support research in academia and the biotech industry. The ADDF's leadership and contributions to the field have played a pivotal role in bringing the first Alzheimer's PET scan (Amyvid®) and blood test (PrecivityAD®) to market, as well as fueling the current robust and diverse drug pipeline. Through the generosity of its donors, the ADDF has awarded more than $290 million to fund over 750 Alzheimer's drug discovery programs, biomarker programs and clinical trials in 20 countries. To learn more, please visit: . SOURCE Alzheimer's Drug Discovery Foundation WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

SAN DIEGO--( BUSINESS WIRE )--SEQSTER PDM Inc. (" SEQSTER "), the leading patient-centric healthcare technology company, announces at the Alzheimer's Association International Conference 2024 in Philadelphia, Pennsylvania it will work with Boston University researchers led by Rhoda Au, PhD, Professor of Anatomy and Neurobiology at Boston University Chobanian & Avedisian School of Medicine, Diagnostics Accelerator (DxA) -funded investigator, and recipient of the Alzheimer’s Drug Discovery Foundation’s (ADDF) 2023 Melvin R. Goodes Prize for Excellence in Alzheimer's Drug Development. The project, funded by the Goodes Prize, will leverage SEQSTER’s 1-Click Records to collect health information, providing the longitudinal data needed for Dr. Au and her team to begin developing an early-stage clinical screening tool for Alzheimer’s. “Early intervention is crucial in managing Alzheimer's, and this project holds promise in identifying individuals at the earliest stages. We chose to use SEQSTER's 1-Click Records because of its instant data connectivity with electronic health records,” states Dr. Au. “As a long-time investigator of the 75-year-old Framingham Heart Study, I view this tool as a way to create a Framingham-like study by aggregating all of a patient’s longitudinal health data. More importantly, SEQSTER empowers participants to decide what medical information they want to contribute, keeping the control of their medical data, while also helping accelerate scientific progress.” SEQSTER's 1-Click Records offers a way to streamline and simplify data collection from multiple sources, unifying a patient’s electronic health record (EHR) data. The interface allows participants to opt in to contributing their data, promoting wider participation in the study and accelerating research. Dr. Au and her team will leverage SEQSTER's 1-Click Records to combine participants’ current and previous health data and will link it to blood based biomarkers and digital cognitive assessments they will be conducting. Dr. Au hopes that the breadth of this data will help her develop an AI-powered screening tool that can identify whether patients are at a higher risk for Alzheimer’s or are even subtly symptomatic. “We know that Alzheimer’s pathology appears at least 20 years before symptoms present, and we don’t yet have the biomarkers or diagnostic tools to identify these changes in real-time,” says Howard Fillit, MD, Co-Founder and Chief Science Officer of the ADDF. “Dr. Au is a pioneer in the development of digital biomarkers and screening tools, and we hope her research will enable early diagnosis and intervention for Alzheimer’s, which researchers believe could have a profound impact on the progression of the disease.” In 2015, Former Warner-Lambert CEO and Chairman, Melvin R. Goodes, and his family established The Melvin R. Goodes Prize for Excellence in Alzheimer’s Drug Discovery alongside the ADDF. The award offers a $150,000 grant to support the winner’s future research. Dr. Rhoda Au was selected as the Goodes Prize Honoree in 2023 , and this project is being funded with her prize money. “This collaboration is another demonstration of our commitment to impact Alzheimer’s Disease while supporting individuals and their caregivers,” adds Ardy Arianpour, CEO & Co-Founder of SEQSTER. “As people may know, this is very personal for me as Alzheimer’s Disease struck both my maternal and paternal grandmothers and I will stop at nothing to fight to find a cure. By combining SEQSTER's 1-Click Records with Boston University's innovative research approach, I envision a future where this collaboration transforms the landscape of Alzheimer's screening, providing individuals and families with an accessible and efficient tool for early detection.” About The Alzheimer’s Drug Discovery Foundation (ADDF) Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer's disease. The ADDF is the only public charity solely focused on funding the development of drugs for Alzheimer's, employing a venture philanthropy model to support research in academia and the biotech industry. The ADDF's leadership and contributions to the field have played a pivotal role in bringing the first Alzheimer's PET scan (Amyvid®) and blood test (PrecivityAD®) to market, as well as fueling the current robust and diverse drug pipeline. Through the generosity of its donors, the ADDF has awarded more than $290 million to fund over 750 Alzheimer's drug discovery programs, biomarker programs and clinical trials in 20 countries. To learn more, please visit: http://www.alzdiscovery.org/ . ABOUT Boston University Founded in 1839, Boston University is an internationally recognized institution of higher education and research. With nearly 37,000 students, it is one of the largest private residential universities in the United States. BU consists of 17 schools and colleges, along with the Faculty of Computing & Data Sciences and a number of multi-disciplinary centers and institutes integral to the University's research and teaching mission. In 2012, BU joined the Association of American Universities (AAU), a consortium of leading research universities in the United States and Canada. ABOUT SEQSTER SEQSTER is the leading healthcare technology company that breaks down health data silos at scale. Its enterprise operating system aggregates disparate health data sources into a single, 360-degree view of a patient in real-time, solving a multitude of challenges for life sciences, patient engagement and data interoperability. SEQSTER has nationwide coverage of EHRs from hospitals and medical groups, genomic DNA, wearables, pharmacy and social determinants of health data. Through its customizable white-label approach, SEQSTER provides accelerated access to de-identified, tokenized, real-time data and comprehensive curated data to address critical needs across the healthcare continuum. SEQSTER is privately held and headquartered in San Diego. To learn more about SEQSTER, please contact us at info@seqster.com or visit www.seqster.com .